Caribou Biosciences, Inc. (CRBU)
CRBU Stock Price Chart
Explore Caribou Biosciences, Inc. interactive price chart. Choose custom timeframes to analyze CRBU price movements and trends.
CRBU Company Profile
Discover essential business fundamentals and corporate details for Caribou Biosciences, Inc. (CRBU) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Biotechnology
IPO Date
23 Jul 2021
Employees
147.00
Website
https://cariboubio.comCEO
Rachel E. Haurwitz
Description
Caribou Biosciences, Inc. operates as a clinical-stage biopharmaceutical firm dedicated to pioneering genome-edited allogeneic cell therapies. These cutting-edge treatments are engineered to address both hematologic malignancies (blood cancers) and solid tumors, serving patients across the United States and internationally. Among its primary therapeutic candidates are CB-010, an allogeneic anti-CD19 CAR-T cell therapy currently undergoing Phase 1 clinical trials for relapsed or refractory B cell non-Hodgkin lymphoma, and CB-011, an allogeneic anti-BCMA CAR-T cell therapy targeting relapsed or refractory multiple myeloma. Caribou Biosciences is additionally developing CB-012, an allogeneic anti-CD371 CAR-T cell therapy for relapsed or refractory acute myeloid leukemia, along with CB-020, an allogeneic CAR-NK cell therapy aimed at solid tumors. The company also maintains a collaborative agreement with AbbVie Manufacturing Management Unlimited Company for the joint advancement of CAR-T cell therapies. Founded in 2011, Caribou Biosciences' headquarters are located in Berkeley, California.
CRBU Financial Timeline
Browse a chronological timeline of Caribou Biosciences, Inc. corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 11 Aug 2026
EPS estimate is -$0.33, while revenue estimate is $2.28m.
Earnings released on 7 May 2026
EPS came in at -$0.26 surpassing the estimated -$0.33 by +21.21%, while revenue for the quarter reached $2.40m , beating expectations by +8.33%.
Earnings released on 5 Mar 2026
EPS came in at -$0.28 surpassing the estimated -$0.33 by +15.15%, while revenue for the quarter reached $3.94m , beating expectations by +78.57%.
Earnings released on 12 Nov 2025
EPS came in at -$0.30 surpassing the estimated -$0.36 by +16.67%, while revenue for the quarter reached $2.20m , beating expectations by +12.32%.
Earnings released on 12 Aug 2025
EPS came in at -$0.35 surpassing the estimated -$0.40 by +12.50%, while revenue for the quarter reached $2.67m , beating expectations by +74.09%.
Earnings released on 8 May 2025
EPS came in at -$0.43 matching the estimated -$0.43, while revenue for the quarter reached $2.35m , beating expectations by +27.09%.
Earnings released on 10 Mar 2025
EPS came in at -$0.39 surpassing the estimated -$0.40 by +2.50%, while revenue for the quarter reached $2.08m , missing expectations by -1.39%.
Earnings released on 6 Nov 2024
EPS came in at -$0.38 surpassing the estimated -$0.44 by +13.64%, while revenue for the quarter reached $2.02m , missing expectations by -34.23%.
Earnings released on 6 Aug 2024
EPS came in at -$0.42 surpassing the estimated -$0.45 by +6.67%, while revenue for the quarter reached $3.46m , beating expectations by +13.69%.
Earnings released on 7 May 2024
EPS came in at -$0.46 falling short of the estimated -$0.39 by -17.95%, while revenue for the quarter reached $2.43m , beating expectations by +0.51%.
Earnings released on 11 Mar 2024
EPS came in at -$0.39 falling short of the estimated -$0.22 by -77.27%, while revenue for the quarter reached $3.56m , missing expectations by -10.02%.
Earnings released on 7 Nov 2023
EPS came in at -$0.12 surpassing the estimated -$0.38 by +68.42%, while revenue for the quarter reached $23.66m , beating expectations by +618.85%.
Earnings released on 8 Aug 2023
EPS came in at -$0.48 surpassing the estimated -$0.49 by +2.04%, while revenue for the quarter reached $3.76m , beating expectations by +21.99%.
Earnings released on 9 May 2023
EPS came in at -$0.46 surpassing the estimated -$0.48 by +4.17%, while revenue for the quarter reached $3.50m , beating expectations by +27.35%.
Earnings released on 9 Mar 2023
EPS came in at -$0.44 surpassing the estimated -$0.47 by +6.38%, while revenue for the quarter reached $3.69m , beating expectations by +20.34%.
Earnings released on 8 Nov 2022
EPS came in at -$0.44 surpassing the estimated -$0.48 by +8.33%, while revenue for the quarter reached $3.30m , missing expectations by -10.73%.
Earnings released on 9 Aug 2022
EPS came in at -$0.46 falling short of the estimated -$0.37 by -24.32%, while revenue for the quarter reached $4.19m , beating expectations by +46.57%.
Earnings released on 9 May 2022
EPS came in at -$0.35 matching the estimated -$0.35, while revenue for the quarter reached $2.66m , missing expectations by -16.75%.
Earnings released on 21 Mar 2022
EPS came in at -$0.34 matching the estimated -$0.34, while revenue for the quarter reached $2.56m , missing expectations by -38.64%.
Earnings released on 9 Nov 2021
EPS came in at -$0.46 falling short of the estimated -$0.12 by -280.17%, while revenue for the quarter reached $3.98m , missing expectations by -75.90%.
Earnings released on 2 Sept 2021
EPS came in at -$1.55 falling short of the estimated $0.42 by -469.05%, while revenue for the quarter reached $1.48m .
Earnings released on 23 Jul 2021
EPS came in at -$0.48 , while revenue for the quarter reached $1.59m .
CRBU Stock Performance
Access detailed CRBU performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.
